---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-25-000032"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:36:32.458892+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing

## Summary
- Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.
- Mark Crossley stepped down as CEO and director; separation terms previously filed.
- Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.
- All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.
- New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1.

## SEC filing metadata
- accession: 0001625297-25-000032
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 1.01, 5.03, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/indv-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-25-000032
- JSON: https://secwatch.observer/filing/0001625297-25-000032.json
- Plain text: https://secwatch.observer/filing/0001625297-25-000032.txt

## Source-grounded claims
- claim_id: ce85a30096
  claim: Mark Crossley departed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: Also, pursuant to his separation agreement, Mark Crossley stepped down as CEO of the Company and as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm
- claim_id: fa9a64af69
  claim: Joe Ciaffoni was appointed as Chief Executive Officer at Indivior Pharmaceuticals, Inc..
  evidence_excerpt: Following shareholder approval of the Company’s Directors’ Remuneration Policy, the Company and Joe Ciaffoni agreed that his employment as CEO would commence on May 8, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000032/0001625297-25-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.